{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T07:05:13Z","timestamp":1783926313164,"version":"3.55.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-026-04699-0","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T06:11:18Z","timestamp":1783923078000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative analysis of IDegLira versus insulin glargine in short-term intensive therapy for overweight or obese patients with type 2 diabetes mellitus"],"prefix":"10.1007","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-5860-0222","authenticated-orcid":false,"given":"Yaping","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6267-3118","authenticated-orcid":false,"given":"Xiaolei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3489-4169","authenticated-orcid":false,"given":"Liwu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"key":"4699_CR1","volume-title":"IDF Diabetes Atlas","author":"International Diabetes Federation(IDF)","year":"2022","unstructured":"International Diabetes Federation(IDF), IDF Diabetes Atlas, 10th edn. (International Diabetes Federation(IDF), Brussels, 2022)","edition":"10"},{"issue":"3","key":"4699_CR2","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.ecl.2021.05.013","volume":"50","author":"MG Tinajero","year":"2021","unstructured":"M.G. Tinajero, V.S. Malik, An Update on the Epidemiology of Type 2 Diabetes: A Global Perspective. Endocrinol. Metab. Clin. North. Am. 50(3), 337\u2013355 (2021)","journal-title":"Endocrinol. Metab. Clin. North. Am."},{"key":"4699_CR3","doi-asserted-by":"publisher","first-page":"1161521","DOI":"10.3389\/fendo.2023.1161521","volume":"14","author":"R Ruze","year":"2023","unstructured":"R. Ruze, T. Liu, X. Zou et al., Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments. Front. Endocrinol. (Lausanne). 14, 1161521 (2023)","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"4699_CR4","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.molmet.2019.12.014","volume":"34","author":"MP Czech","year":"2020","unstructured":"M.P. Czech, Mechanisms of insulin resistance related to white, beige, and brown adipocytes. Mol. Metab. 34, 27\u201342 (2020)","journal-title":"Mol. Metab."},{"issue":"8738","key":"4699_CR5","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/0140-6736(91)91164-P","volume":"337","author":"PM McKeigue","year":"1991","unstructured":"P.M. McKeigue, B. Shah, M.G. Marmot, Relation of central obesity and insulin resistance with high diabetes prevalence and cardiovascular risk in South Asians. Lancet. 337(8738), 382\u2013386 (1991)","journal-title":"Lancet"},{"key":"4699_CR6","doi-asserted-by":"publisher","first-page":"e080122","DOI":"10.1136\/bmj-2024-080122","volume":"387","author":"L Liu","year":"2024","unstructured":"L. Liu, W. Ke, H. Li et al., Intense simplified strategy for newly diagnosed type 2 diabetes in patients with severe hyperglycaemia: multicentre, open label, randomised trial. BMJ. 387, e080122 (2024)","journal-title":"BMJ"},{"issue":"5","key":"4699_CR7","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1111\/dom.14970","volume":"25","author":"Y Li","year":"2023","unstructured":"Y. Li, D. Yu, L. Guo et al., Efficacy and safety of basal-first titration order in individuals with type 2 diabetes receiving short-term intensive insulin therapy: An exploratory analysis of BEYOND V. Diabetes Obes. Metab. 25(5), 1221\u20131228 (2023)","journal-title":"Diabetes Obes. Metab."},{"issue":"1","key":"4699_CR8","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1038\/s41598-020-58574-7","volume":"10","author":"K Nakashima","year":"2020","unstructured":"K. Nakashima, N. Okamura, H. Sanefuji, H. Kaneto, Practical application of short-term intensive insulin therapy based on the concept of treat to target to reduce hypoglycaemia in routine clinical site. Sci. Rep. 10(1), 1552 (2020)","journal-title":"Sci. Rep."},{"issue":"Suppl 1","key":"4699_CR9","doi-asserted-by":"publisher","first-page":"S125","DOI":"10.2337\/dc22-S009","volume":"45","author":"American Diabetes Association Professional Practice Committee","year":"2022","unstructured":"American Diabetes Association Professional Practice Committee, 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022. Diabetes Care. 45(Suppl 1), S125\u2013S143 (2022)","journal-title":"Diabetes Care"},{"issue":"4","key":"4699_CR10","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1177\/0897190017753041","volume":"32","author":"T Yang","year":"2019","unstructured":"T. Yang, B.T. Cutshall, A. Tatara, M. Ruegger, Combined Insulin and GLP-1 Receptor Agonists: Simplifying Treatment or Adding Obstacles? J. Pharm. Pract. 32(4), 447\u2013449 (2019)","journal-title":"J. Pharm. Pract."},{"issue":"9","key":"4699_CR11","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.2337\/dc22-2426","volume":"46","author":"RJ Galindo","year":"2023","unstructured":"R.J. Galindo, B. Moazzami, M.F. Scioscia et al., A Randomized Controlled Trial Comparing the Efficacy and Safety of IDegLira Versus Basal-Bolus in Patients With Poorly Controlled Type 2 Diabetes and Very High HbA1c\u2009\u2265\u20099\u201315%: DUAL HIGH Trial. Diabetes Care. 46(9), 1640\u20131645 (2023)","journal-title":"Diabetes Care"},{"issue":"11","key":"4699_CR12","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/S2213-8587(14)70174-3","volume":"2","author":"SC Gough","year":"2014","unstructured":"S.C. Gough, B. Bode, V. Woo et al., Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. Lancet Diabetes Endocrinol. 2(11), 885\u2013893 (2014)","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"4","key":"4699_CR13","first-page":"419","volume":"29","author":"X Li","year":"2004","unstructured":"X. Li, Z.G. Zhou, H.Y. Yuan et al., Replacement of insulin by fasting C-peptide in modified homeostasis model assessment to evaluate insulin resistance and islet\u03b2cell function[J]. J. Cent. South. University: Med. Ed. 29(4), 419\u2013423 (2004)","journal-title":"J. Cent. South. University: Med. Ed."},{"issue":"11","key":"4699_CR14","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1111\/1753-0407.13203","volume":"13","author":"Y Wang","year":"2021","unstructured":"Y. Wang, X. Zou, X. Cai et al., Urinary C-peptide\/creatinine ratio: A useful biomarker of insulin resistance and refined classification of type 2 diabetes mellitus. J. Diabetes. 13(11), 893\u2013904 (2021)","journal-title":"J. Diabetes"},{"issue":"3","key":"4699_CR15","doi-asserted-by":"publisher","first-page":"644","DOI":"10.2337\/dc13-1102","volume":"37","author":"K Yoda","year":"2014","unstructured":"K. Yoda, M. Inaba, K. Hamamoto et al., Association between glycemic control and morning blood pressure surge with vascular endothelial dysfunction in type 2 diabetic patients. Diabetes Care. 37(3), 644\u2013650 (2014)","journal-title":"Diabetes Care"},{"issue":"11","key":"4699_CR16","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.2337\/dc18-1131","volume":"41","author":"J Lu","year":"2018","unstructured":"J. Lu, X. Ma, J. Zhou et al., Association of Time in Range, as Assessed by Continuous Glucose Monitoring, With Diabetic Retinopathy in Type 2 Diabetes. Diabetes Care. 41(11), 2370\u20132376 (2018)","journal-title":"Diabetes Care"},{"issue":"3","key":"4699_CR17","doi-asserted-by":"publisher","first-page":"400","DOI":"10.2337\/dc18-1444","volume":"42","author":"RW Beck","year":"2019","unstructured":"R.W. Beck, R.M. Bergenstal, T.D. Riddlesworth et al., Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials. Diabetes Care. 42(3), 400\u2013405 (2019)","journal-title":"Diabetes Care"},{"issue":"3","key":"4699_CR18","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s00592-024-02361-7","volume":"62","author":"ME Malighetti","year":"2025","unstructured":"M.E. Malighetti, L. Molteni, E. Orsi et al., IDegLira improves time in range in a cohort of patients with type 2 diabetes: TiREX study. Acta Diabetol. 62(3), 367\u2013374 (2025)","journal-title":"Acta Diabetol."},{"issue":"3","key":"4699_CR19","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1177\/19322968221149041","volume":"18","author":"A Philis-Tsimikas","year":"2024","unstructured":"A. Philis-Tsimikas, V.R. Aroda, De C. Block et al., Higher Derived Time in Range With IDegLira Versus Insulin Glargine U100 in People With Type 2 Diabetes. J. Diabetes Sci. Technol. 18(3), 653\u2013659 (2024)","journal-title":"J. Diabetes Sci. Technol."},{"issue":"2","key":"4699_CR20","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s40265-019-01245-3","volume":"80","author":"S Harris","year":"2020","unstructured":"S. Harris, M.J. Abrahamson, A. Ceriello et al., Clinical Considerations When Initiating and Titrating Insulin Degludec\/Liraglutide (IDegLira) in People with Type 2 Diabetes. Drugs. 80(2), 147\u2013165 (2020)","journal-title":"Drugs"},{"issue":"8","key":"4699_CR21","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/S2213-8587(19)30198-6","volume":"7","author":"S Bellary","year":"2019","unstructured":"S. Bellary, A.A. Tahrani, A.H. Barnett, IDegLira: combining efficacy, durability, and convenience? Lancet Diabetes Endocrinol. 7(8), 584\u2013585 (2019)","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"1 Suppl 1","key":"4699_CR22","doi-asserted-by":"publisher","first-page":"S167","DOI":"10.2337\/dc25-S008","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","unstructured":"American Diabetes Association Professional Practice Committee, 8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes-2025. Diabetes Care. 48(1 Suppl 1), S167\u2013S180 (2025)","journal-title":"Diabetes Care"},{"key":"4699_CR23","doi-asserted-by":"publisher","first-page":"e076410","DOI":"10.1136\/bmj-2023-076410","volume":"384","author":"H Yao","year":"2024","unstructured":"H. Yao, A. Zhang, D. Li et al., Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ. 384, e076410 (2024)","journal-title":"BMJ"},{"issue":"2","key":"4699_CR24","doi-asserted-by":"publisher","first-page":"164","DOI":"10.15605\/jafes.034.02.07","volume":"34","author":"FP Bautista","year":"2019","unstructured":"F.P. Bautista, G. Jr Jasul, O.A. Dampil, Insulin Resistance and \u03b2-Cell Function of Lean versus Overweight or Obese Filipino Patients with Newly Diagnosed Type 2 Diabetes Mellitus. J. ASEAN Fed. Endocr. Soc. 34(2), 164\u2013170 (2019)","journal-title":"J. ASEAN Fed. Endocr. Soc."},{"issue":"2","key":"4699_CR25","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1007\/s41999-025-01271-3","volume":"17","author":"F De Mancinetti","year":"2026","unstructured":"F. Mancinetti, D. Xenos, De M. Fano et al., Switching from insulin injections to degludec\/liraglutide in older frail persons: 6-month body composition remodelling. Eur. Geriatr. Med. 17(2), 977\u2013984 (2026)","journal-title":"Eur. Geriatr. Med."},{"key":"4699_CR26","doi-asserted-by":"publisher","first-page":"108487","DOI":"10.1016\/j.diabres.2020.108487","volume":"170","author":"W Guo","year":"2020","unstructured":"W. Guo, W. Tian, L. Lin, X. Xu, Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial. Diabetes Res. Clin. Pract. 170, 108487 (2020)","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"2","key":"4699_CR27","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1177\/1932296815610124","volume":"10","author":"JJ Holst","year":"2015","unstructured":"J.J. Holst, J.B. Buse, H.W. Rodbard et al., IDegLira Improves Both Fasting and Postprandial Glucose Control as Demonstrated Using Continuous Glucose Monitoring and a Standardized Meal Test. J. Diabetes Sci. Technol. 10(2), 389\u2013397 (2015)","journal-title":"J. Diabetes Sci. Technol."},{"key":"4699_CR28","doi-asserted-by":"publisher","first-page":"1643386","DOI":"10.3389\/fendo.2025.1643386","volume":"16","author":"Y Liu","year":"2025","unstructured":"Y. Liu, X. Li, J. Yang et al., IDeglira vs insulin degludec for type 2 diabetes: a systematic review and meta-analysis. Front. Endocrinol. (Lausanne). 16, 1643386 (2025)","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"4699_CR29","doi-asserted-by":"publisher","first-page":"3293","DOI":"10.12659\/MSM.907227","volume":"24","author":"Y Li","year":"2018","unstructured":"Y. Li, J. Zheng, Y. Shen et al., Comparative Study of Liraglutide and Insulin Glargine on Glycemic Control and Pancreatic \u03b2-Cell Function in db\/db Mice. Med. Sci. Monit. 24, 3293\u20133300 (2018)","journal-title":"Med. Sci. Monit."},{"issue":"2","key":"4699_CR30","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/dme.14178","volume":"37","author":"L Meneghini","year":"2020","unstructured":"L. Meneghini, A. Doshi, D. Gouet et al., Insulin degludec\/liraglutide (IDegLira) maintains glycaemic control and improves clinical outcomes, regardless of pre-trial insulin dose, in people with type 2 diabetes that is uncontrolled on basal insulin. Diabet. Med. 37(2), 267\u2013276 (2020)","journal-title":"Diabet. Med."},{"issue":"1","key":"4699_CR31","doi-asserted-by":"publisher","first-page":"e390","DOI":"10.1002\/edm2.390","volume":"6","author":"ZJ Taybani","year":"2023","unstructured":"Z.J. Taybani, B. B\u00f3tyik, A. Gyimesi, M. Katk\u00f3, T. V\u00e1rkonyi, One-year safety and efficacy results of insulin treatment simplification with IDegLira in type 2 diabetes. Endocrinol. Diabetes Metab. 6(1), e390 (2023)","journal-title":"Endocrinol. Diabetes Metab."},{"issue":"5","key":"4699_CR32","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.2337\/dc17-1114","volume":"41","author":"LK Billings","year":"2018","unstructured":"L.K. Billings, A. Doshi, D. Gouet et al., Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin: The DUAL VII Randomized Clinical Trial. Diabetes Care. 41(5), 1009\u20131016 (2018)","journal-title":"Diabetes Care"},{"key":"4699_CR33","doi-asserted-by":"publisher","first-page":"100056","DOI":"10.1016\/j.obpill.2023.100056","volume":"5","author":"HE Bays","year":"2023","unstructured":"H.E. Bays, S. Bindlish, T.L. Clayton, Obesity, diabetes mellitus, and cardiometabolic risk: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2023. Obes. Pillars. 5, 100056 (2023)","journal-title":"Obes. Pillars"},{"key":"4699_CR34","doi-asserted-by":"publisher","first-page":"1585279","DOI":"10.3389\/fpubh.2025.1585279","volume":"13","author":"X Wang","year":"2025","unstructured":"X. Wang, Y. Tao, S. Gao et al., Effects of DRG\/DIP payment reform on hospital pharmacy administration and pharmaceutical services in China: a multicenter cross-sectional study. Front. Public. Health. 13, 1585279 (2025)","journal-title":"Front. Public. Health"},{"issue":"1","key":"4699_CR35","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S2213-8587(22)00319-9","volume":"11","author":"T Battelino","year":"2023","unstructured":"T. Battelino, C.M. Alexander, S.A. Amiel et al., Continuous glucose monitoring and metrics for clinical trials: an international consensus statement. Lancet Diabetes Endocrinol. 11(1), 42\u201357 (2023)","journal-title":"Lancet Diabetes Endocrinol."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-026-04699-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-026-04699-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-026-04699-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T06:11:19Z","timestamp":1783923079000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-026-04699-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4699"],"URL":"https:\/\/doi.org\/10.1007\/s12020-026-04699-0","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,13]]},"assertion":[{"value":"20 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Medical Ethics Committee of the First Hospital of Anhui University of Science and Technology (Ethics Approval No.2025-KY-Y026-001) and is in accordance with the Declaration of Helsinki and registered with the Chinese Clinical Trial Registry.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"225"}}